Exhibit 99.1

RADIATION THERAPY SERVICES HOLDINGS, INC.

RADIATION THERAPY SERVICES REPORTS

THIRD QUARTER 2013 FINANCIAL RESULTS

Third Quarter 2013 Highlights:

·                  Total revenues of $181.0 million, up 8.1% year-over-year

·                  Same-market treatments per day increased 6.4%, including recent  acquisitions complimented by expansion of ICC model and Physician Liaison program which resulted in organic treatments per day growth of 3.7%

·                  International revenues of $24.6 million, up 19.1% year-over-year

·                  Pro Forma Adjusted EBITDA of $23.2 million

Recent Business Highlights:

·                  Completed the acquisition of OnCure Holdings, Inc. (“Oncure”) in October, adding significant scale and opportunity for cost synergies and revenue growth

·                  Received $50 million in additional term commitments utilized for the acquisition of Oncure and to further support other growth initiatives

·                  Signed contract extending relationship with Northern Westchester Hospital for an additional 8 years

·                  Entered value added services agreement with Mercy Medical Center, part of Dignity Health, to provide oncology services to the hospital in strategic Redding, California market

·                  Closed acquisition of Tijuana, Mexico facility; on schedule to re-launch with advanced technologies by 1Q 2014

FORT MYERS, FL, November 6, 2013 — Radiation Therapy Services Holdings, Inc (“Radiation Therapy” or “the Company”), a leading operator of radiation therapy centers, announced today its financial results for the third quarter ended September 30, 2013.

Dr. Daniel Dosoretz, President and Chief Executive Officer, commented, “The third quarter results reflect the strength of our model and the revenue and EBITDA growth our strategy is designed to achieve.  It is a direct result of our organic growth initiatives such as our Physician Liaison and ICC programs along the upside these programs provide to same-market acquisitions and joint ventures. We are extremely pleased with this performance, especially in the face of the approximately 9% CMS RVU cuts for 2013. From a volume perspective, domestic same-market treatments per day, which include same market acquisitions, grew by 6.4% year-over-year, with organic treatments per day increasing 3.7%. Additionally, our International business has

performed incredibly well in the quarter, producing 19.1% year-over-year revenue growth driven by use of more sophisticated treatment modalities and we believe is positioned for a strong 2014.

He continued, “We are especially pleased to have closed the acquisition of Oncure which is a transformational event for the Company and the largest acquisition in our history. We believe Oncure provides a key component to accelerating our long term growth initiatives. The purchase results in a substantial increase in scale by adding 25% more locations, excellent physician resources, strengthened leadership position in existing markets and a significant presence in new markets, where we intend to quickly take steps to expand via our integrated cancer care model.

Dr. Dosoretz concluded, “We believe we are approaching 2014 with significant momentum, driven by growth in census and a strong business model. We believe our evolution over the past decade into a global, physician—led provider of integrated cancer care services positions us well for continued and sustainable long-term growth. We have also proven that our model is efficient and capable of driving value in a healthcare environment that demands the highest quality care at a predictable and affordable cost. Now more than ever, we have the strategy, integrated model, resources and leadership to accelerate our growth into 2014 and beyond.”

Third Quarter 2013 Results

Total revenues for the third quarter of 2013 were $181.0 million, compared to $167.5 million in revenues in the same quarter of 2012, an increase of 8.1%. The increase in revenue was principally due to increased domestic census, accretive joint ventures and acquisitions, one more treatment day than in the third quarter of 2012 and international revenue growth, offset by lower reimbursement rates.

Domestic total treatments per day increased 6.4% in the third quarter of 2013, which includes treatment volume from our same market acquisition of Premiere/SIU. This was driven by expansion of our integrated cancer care model, growth in total treatments and increased referrals through the Company’s physician liaison program. Domestic same practice therapy revenue per treatment decreased 4.2% from the third quarter of 2012, primarily due to reductions in the CMS reimbursement rates, partially offset by improvements in treatment mix and managed care pricing. Total RVUs per day at same practice domestic freestanding centers decreased 1.9% in the third quarter versus the same period of the prior year due to reductions in the reimbursement rates.

Adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation and other non-cash and pro forma items (“Pro Forma Adjusted EBITDA”) in the third quarter of 2013 was $23.2 million, or 12.8% of total pro forma revenues, compared to $22.6 million, or 13.5% of total pro forma revenues, in the third quarter of 2012. Pro Forma Adjusted EBITDA margins declined in the current quarter versus the prior year period primarily due to reductions in the Medicare reimbursement rate, the growth in establishing integrated cancer care practices, and investments made in key personnel. A reconciliation of net loss attributable to Radiation Therapy Services Holdings, Inc., determined in accordance with generally accepted accounting principles, to Pro Forma Adjusted EBITDA and total revenues, determined in accordance with generally accepted accounting principles, to total pro forma revenues for the quarters ended September 30, 2013 and 2012 is included in the attached supplemental financial information.

Income tax expense in the third quarter of 2013 was $1.7 million, compared to the same income tax expense in the third quarter of 2012.  The net loss for the third quarter of 2013 was $25.1 million, compared to a net loss of $90.5 million in the third quarter of 2012.

Recent Developments

In October, the Company completed the acquisition of Oncure for approximately $125.0 million, including $42.5 million in cash and up to $82.5 million in assumed debt ($7.5 million of this assumed debt is subject to escrow conditions and will be released assuming certain Oncure centers achieve a minimum level of EBITDA). This transformative event is the largest acquisition in the Company’s history and increases the number of radiation centers by over 25%. The strategic addition is expected to provide operating synergies, broaden the Company’s ability to provide integrated cancer care across a larger spectrum and offer significant revenue upside potential.

In August, Radiation Therapy amended its $140 million revolving credit facility creating additional capacity to execute its long term growth strategy. The amendment reduces the overall revolving loan to $100 million. An additional $50 million was combined with the $40 million balance of revolving credit facility into a newly formed $90 million term loan. The additional term loan commitments were used to fund the acquisition of Oncure. The revolver and term loan each have a maturity date of October 15, 2016.

In July, Radiation Therapy signed a contract to extend its relationship with Northern Westchester Hospital in Westchester County, NY for an additional 8 years. As a result the Company will continue to provide advanced technical and administrative services to the hospital, continuing its longstanding partnership to serve patients in the region.

In September, the Company signed a value added services agreement with Mercy Medical Center in Redding, CA, part of Dignity Health, to provide oncology services. This agreement adds to Radiation Therapy’s presence in the strategic market of California, where the Company also recently expanded operations through its acquisition of Oncure.

The Company’s plan to upgrade its newly acquired Tijuana, Mexico facility by installing advanced radiation oncology technology is moving forward as planned. The Company anticipates opening the center during the first quarter of 2014.

Conference Call

Management will host a conference call on Thursday, November 7, 2013 at 11:00 a.m. ET to discuss its financial results. The dial-in numbers are (877) 407-9039 for domestic callers and (201) 689-8470 for international callers.  In addition, a telephonic replay of the call will be available until November 21, 2013.  The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers.  Please use the conference ID number 13572587 to access the replay.

A live webcast and webcast replay of the call will also be available from the Events section on the corporate web site at www.rtsx.com.

About Radiation Therapy Services Holdings, Inc.

Radiation Therapy Services is the largest global, physician-led provider of Integrated Cancer Care Services. The Company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. The Company operates 166 treatment centers, including 133 centers located in 16 U.S. states. The Company also operates 33 centers located in six countries in Latin America. The Company holds market leading positions in most of its domestic local markets and abroad.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended.  Statements preceded by, followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans”, “may increase”, “forecast” and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. Forward-looking statements are based on management’s current expectations or beliefs about the Company’s future plans, expectations and objectives, including, but not limited to, the Company’s expected financial results and estimates for 2013 and the effects of the CMS’s Final Rule for the 2014Physician Fee Schedule on its results.  These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause the actual results to differ materially from those projected in these forward-looking statements including, but not limited to reductions in Medicare reimbursement, healthcare reform, decreases in payments by managed care organizations and other commercial payers  and other risk factors that may be described from time to time in the Company’s filings with the Securities and Exchange Commission.  Readers of this release are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date stated, or if no date is stated, as of the date of this press release. The Company undertakes no obligation to publicly update or revise the forward-looking statements contained herein to reflect changed events or circumstances after the date of this release, unless required by law.

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share amounts)

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

Supplemental Financial Information (Unaudited)

Reconciliation of Total Pro-forma Revenue and Pro-forma Adjusted EBITDA to Net Loss Attributable

to Radiation Therapy Services Holdings, Inc. Shareholder

(1) Pro-forma Adjusted EBITDA is defined as income (loss) before interest expense (net of interest income), income taxes, depreciation and amortization, gain on the sale of an interest in a joint venture, early extinguishment of debt, fair value adjustment of earn-out liability, impairment loss, foreign currency derivative contract loss (gain), management fees accrued to our sponsor, non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to repairs and maintenance, non-cash equipment rent, sale-lease back adjustments, acquisition-related costs, other expenses including loss on sale of assets, severance payments related to termination of employee staff reductions, tail premiums on termed physicians, franchise taxes, costs relating to consulting services on Medicare reimbursement, litigation settlements with physicians, expenses associated with the provision for income taxes, costs associated with tradename and rebranding initiatives, expenses associated with idle / closed radiation therapy treatment facilities and pro-forma full period effect of acquisition EBITDA

(a) Pro-forma amounts related to adjustments to total revenues and Pro-forma Adjusted EBITDA to reflect the full period effect of our acquisitions and Value Added Services contracts completed during 2013 and 2012. The adjustments reflect the impact to our total revenues and Pro-forma Adjusted EBITDA as if the acquisitions and Value Added Services contracts had occurred at the beginning of the year.

(b) Management fees are fees accrued to our sponsor, Vestar Capital Partners.

(c) Non-cash expenses including costs relating to stock compensation, amortization of straight-line rent, amortization of capital expenditures relating to warranty arrangements amortized to repairs and maintenance and non-cash equipment rent.

(d) Sale-lease back adjustments relates to the adjustment of benefit derived from the classification of operating leases as finance obligations reflecting a reclassification of interest expense and depreciation and amortization expense as rent expense.

(e) Acquisition related costs associated with ASC 805, Business Combinations, including professional fees, corporate development, integration and due diligence costs relating to the acquisition of medical practices.

(f) Other expenses include loss on sale of assets, severance payments related to termination of employee staff reductions, tail premiums paid on terminated physicians, franchise taxes and costs relating to consulting services on Medicare reimbursement.

(g) Litigation settlement relates to costs associated with the termination of physicians during 2012 and 2013.

(h) Expenses related to the costs associated with process improvements in the provision for income taxes.

(i) Expenses related to the costs associated with the Company’s tradename and rebranding initiatives.

(j) Expenses associated with idle / closed radiation therapy treatment facilities.

We believe the Pro-forma Adjusted EBITDA provides useful information about our financial performance to investors, lenders, financial analysts and rating agencies since these groups have historically used EBITDA-related measures in the healthcare industry, along with other measures, to estimate the value of a company, to make informed investment decisions, to evaluate a company’s leverage capacity and its ability to meet its debt service requirements. Pro-forma Adjusted EBITDA eliminates the uneven effect of non-cash depreciation of tangibles assets and amortization of intangible assets, much of which results from acquisitions accounted for under the purchase method of accounting. Pro-forma Adjusted EBITDA is also used by us to measure individual performance for incentive compensation purposes and as an analytical indicator for purposes of allocating resources to our operating business and assessing their performance, both internally and relative to our peers, as well as to evaluate the performance of our operating management teams, and for purposes in the calculation of debt covenants and related disclosures.

Pro-forma Adjusted EBITDA is not intended as a substitute for net income (loss) attributable to Radiation Therapy Services Holdings, Inc. shareholder, operating cash flows or other cash flow data determined in accordance with accounting principles generally accepted in the United States. Due to varying methods of calculation, Pro-forma Adjusted EBITDA as presented may not be comparable to similarly titled measures of other companies.

RADIATION THERAPY SERVICES HOLDINGS, INC.

KEY OPERATING STATISTICS

(unaudited)

###